Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.

Literature DB >> 2229132

Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.

H D vom Orde¹, H Reile, R Müller, R Gust, G Bernhardt, T Spruss, H Schönenberger, T Burgemeister, A Mannschreck.

Abstract

The enantiomeric [1,2-bis(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes were synthesized and tested on the hormone-sensitive human MCF7 breast cancer cell line and on the P388 leukemia of the mouse. They showed a strong and comparable activity on both tumor models.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1990 PMID： 2229132 DOI： 10.1007/bf01612989

Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN： 0171-5216 Impact factor: 4.553

11 in total

1. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part IV: Biological evaluation--in vivo studies on the P 388 leukemia.

Authors: H Reile; T Spruss; G Bernhardt; R Müller; R Gust; H Schönenberger
Journal: Arch Pharm (Weinheim) Date: 1991-07 Impact factor: 3.751

2. Computerized determination of growth kinetic curves and doubling times from cells in microculture.

Authors: H Reile; H Birnböck; G Bernhardt; T Spruss; H Schönenberger
Journal: Anal Biochem Date: 1990-06 Impact factor: 3.365

Review 3. The seed stock concept and quality control for cell lines.

Authors: R J Hay
Journal: Anal Biochem Date: 1988-06 Impact factor: 3.365

4. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.

Authors: M Jennerwein; R Gust; R Müller; H Schönenberger; J Engel; M R Berger; D Schmähl; S Seeber; R Osieka; G Atassi
Journal: Arch Pharm (Weinheim) Date: 1989-01 Impact factor: 3.751

5. A human cell line from a pleural effusion derived from a breast carcinoma.

Authors: H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal: J Natl Cancer Inst Date: 1973-11 Impact factor: 13.506

6. Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl) ethylenediamine]dichloroplatinum(II)-complexes, Part II: Biological properties.

Authors: M Jennerwein; R Gust; R Müller; H Schönenberger; J Engel; M R Berger; D Schmähl; S Seeber; R Osieka; G Atassi
Journal: Arch Pharm (Weinheim) Date: 1989-02 Impact factor: 3.751

7. Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes, III: Evaluation of the mammary tumor inhibiting properties.

Authors: H Reile; T Spruss; R Müller; R Gust; G Bernhardt; H Schönenberger; J Engel
Journal: Arch Pharm (Weinheim) Date: 1990-05 Impact factor: 3.751

8. Dichloro[1,2-bis(4-hydroxyphenyl)ethylenediamine]platinum(II) complexes: an approach to develop compounds with a specific effect on the hormone-dependent mammary carcinoma.

Authors: B Wappes; M Jennerwein; E von Angerer; H Schönenberger; J Engel; M Berger; K H Wrobel
Journal: J Med Chem Date: 1984-10 Impact factor: 7.446

9. Preparation of antitumor platinum(II) complexes of 1,2-diphenylethylenediamine isomers and their interactions with DNA and its purine moieties.

Authors: M Noji; Y Gohchi; Y Kidani
Journal: Chem Biol Interact Date: 1984-09-01 Impact factor: 5.192

10. [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.

Authors: R Müller; R Gust; G Bernhardt; C Keller; H Schönenberger; S Seeber; R Osieka; A Eastman; M Jennerwein
Journal: J Cancer Res Clin Oncol Date: 1990 Impact factor: 4.553

3 in total

1. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.

Authors: G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal: J Cancer Res Clin Oncol Date: 1992 Impact factor: 4.553

2. [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.

Authors: G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal: J Cancer Res Clin Oncol Date: 1992 Impact factor: 4.553

3. Different response of murine and human mammary tumour models to a series of diastereoisomeric [1,2-bis(difluorophenyl) ethylenediamine]dichloroplatinum(II) complexes.

Authors: T Spruss; G Bernhardt; E Schickaneder; H Schönenberger
Journal: J Cancer Res Clin Oncol Date: 1991 Impact factor: 4.553

3 in total